- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin, Quetiapine
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Parkinson Disease, Epilepsy, Alzheimer's Disease, Stroke, Autism, Depression, Schizophrenia
- Interventions
- Transcranial direct current stimulation, MRI
- Device · Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- pimavanserin tartrate, placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 62
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 58 more
- Conditions
- Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin tartrate (ACP-103), Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more
- Conditions
- Healthy, Schizophrenia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 265 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1991 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease
- Interventions
- Cannabidiol, Placebo
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Parkinson Disease
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- State University of New York - Downstate Medical Center
- Other
- Eligibility
- 40 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Healthy Subjects, Schizophrenia, Parkinson Disease
- Interventions
- Oxygen-15 Water
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,039 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1993
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease Psychosis
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Fullerton, California • Miami, Florida + 15 more
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Interventions
- ACP-103
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 13
- States / cities
- Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more
- Conditions
- Parkinson Disease Psychosis
- Interventions
- Real-world, non-interventional
- Other
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 69
- States / cities
- Cullman, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 62 more
- Conditions
- Dementia, Parkinson Disease
- Interventions
- Quetiapine
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 18 more
- Conditions
- Dementia-related Psychosis
- Interventions
- Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 27
- States / cities
- Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
- Conditions
- Parkinson Disease, Parkinson Disease Psychosis, Hallucinations, Delusion
- Interventions
- Observation of minor phenomena
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Parkinson's Disease Psychosis, Dementia With Lewy Bodies
- Interventions
- Pimavanserin, Quetiapine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- Not listed
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Schizophrenia, Parkinson's Disease
- Interventions
- 18F-Fluoro-L-dopa, O-15 Water
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 502 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson's Disease
- Interventions
- EMD 128130, IV Levodopa
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease Psychosis
- Interventions
- SEP-363856, Placebo capsule
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 105 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 24
- States / cities
- Fresno, California • Los Angeles, California • Riverside, California + 19 more
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- pimavanserin tartrate (ACP-103)
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Danbury, Connecticut
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin tartrate (ACP-103)
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- La Habra, California • Laguna Hills, California • Reseda, California + 22 more
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Parkinson's Disease, Psychotic Disorders
- Interventions
- Melperone HCl, Placebo
- Drug
- Lead sponsor
- Lundbeck LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Bradenton, Florida • Tampa, Florida + 7 more